Kangchen Pharmaceutical (01681.HK) announces its interim results, with a net profit attributable to shareholders of 4.98 billion yuan, a 24.6% year-on-year increase. Its flagship product Niaoduqing maintains its market-leading position.

Financial APP news, Kangcon Pharmaceuticals (01681.HK) released its performance for the six months ending June 30, 2025. The group generated revenue of 1.569 billion yuan during the period, a year-on-year increase of 23.7%. The net profit attributable to equity shareholders of the company was 498 million yuan, a year-on-year increase of 24.6%. Earnings per share were 0.59 yuan. The company plans to distribute an interim dividend of 0.33 yuan per share.